These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 21138720)

  • 21. Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.
    Tidey JW; Monti PM; Rohsenow DJ; Gwaltney CJ; Miranda R; McGeary JE; MacKillop J; Swift RM; Abrams DB; Shiffman S; Paty JA
    Alcohol Clin Exp Res; 2008 Jan; 32(1):58-66. PubMed ID: 18028530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modeling longitudinal drinking data in clinical trials: an application to the COMBINE study.
    DeSantis SM; Bandyopadhyay D; Baker NL; Randall PK; Anton RF; Prisciandaro JJ
    Drug Alcohol Depend; 2013 Sep; 132(1-2):244-50. PubMed ID: 23566774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
    Kranzler HR; Van Kirk J
    Alcohol Clin Exp Res; 2001 Sep; 25(9):1335-41. PubMed ID: 11584154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study.
    Namkoong K; Lee BO; Lee PG; Choi MJ; Lee E
    Alcohol Alcohol; 2003; 38(2):135-41. PubMed ID: 12634260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
    Roos CR; Mann K; Witkiewitz K
    Addict Biol; 2017 Nov; 22(6):1528-1539. PubMed ID: 27480445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment.
    Gueorguieva R; Wu R; Donovan D; Rounsaville BJ; Couper D; Krystal JH; O'Malley SS
    Alcohol; 2012 Mar; 46(2):121-31. PubMed ID: 21925828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients.
    Zarkin GA; Bray JW; Aldridge A; Mitra D; Mills MJ; Couper DJ; Cisler RA;
    Arch Gen Psychiatry; 2008 Oct; 65(10):1214-21. PubMed ID: 18838638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study.
    Weiss RD; O'malley SS; Hosking JD; Locastro JS; Swift R;
    J Stud Alcohol Drugs; 2008 Nov; 69(6):878-84. PubMed ID: 18925346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.
    Donoghue K; Elzerbi C; Saunders R; Whittington C; Pilling S; Drummond C
    Addiction; 2015 Jun; 110(6):920-30. PubMed ID: 25664494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moderating effects of a craving intervention on the relation between negative mood and heavy drinking following treatment for alcohol dependence.
    Witkiewitz K; Bowen S; Donovan DM
    J Consult Clin Psychol; 2011 Feb; 79(1):54-63. PubMed ID: 21261434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale for combining acamprosate and naltrexone for treating alcohol dependence.
    Mason BJ
    J Stud Alcohol Suppl; 2005 Jul; (15):148-56; discussion 140. PubMed ID: 16223066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review.
    Soyka M; Rösner S
    Curr Drug Abuse Rev; 2008 Nov; 1(3):280-91. PubMed ID: 19630726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The pharmacologic treatment of the alcohol dependence].
    Castro LA; Baltieri DA
    Braz J Psychiatry; 2004 May; 26 Suppl 1():S43-6. PubMed ID: 15729444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.
    Snyder JL; Bowers TG
    Am J Drug Alcohol Abuse; 2008; 34(4):449-61. PubMed ID: 18584575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response.
    Gueorguieva R; Wu R; Krystal JH; Donovan D; O'Malley SS
    Addict Behav; 2013 May; 38(5):2119-27. PubMed ID: 23435273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study characteristics influence the efficacy of substance abuse treatments: A meta-analysis of medications for alcohol use disorder.
    Klemperer EM; Hughes JR; Naud S
    Drug Alcohol Depend; 2018 Sep; 190():229-234. PubMed ID: 30059816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?
    Maisel NC; Blodgett JC; Wilbourne PL; Humphreys K; Finney JW
    Addiction; 2013 Feb; 108(2):275-93. PubMed ID: 23075288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study.
    Worley MJ; Witkiewitz K; Brown SA; Kivlahan DR; Longabaugh R
    Alcohol Clin Exp Res; 2015 Jan; 39(1):93-100. PubMed ID: 25623409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Acamprosate and naltrexone: similar efficacy for relapse].
    Saitz R
    Rev Med Suisse; 2014 Dec; 10(455):2437. PubMed ID: 25752019
    [No Abstract]   [Full Text] [Related]  

  • 40. Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study.
    Gueorguieva R; Wu R; Donovan D; Rounsaville BJ; Couper D; Krystal JH; O'Malley SS
    Drug Alcohol Depend; 2010 Mar; 107(2-3):221-9. PubMed ID: 19969427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.